New evidence for the spasm-of-resistance-vessel concept of ischemic diseases

Medical Hypotheses

Volumn 53, Issue 3, 1999, Pages 200-209

  Hellstrom, H R ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOREGULATION; HYPERTENSION; ISCHEMIA; ISCHEMIC HEART DISEASE; MIGRAINE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RESISTANCE BLOOD VESSEL; RISK FACTOR; STROKE; SYMPTOM; VASOSPASM;

EID: 0032878332     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1998.0746     Document Type: Article

References (166)

1. Hellstrom H. R. The spasm of resistance vessel concept of ischemic heart disease and other ischemic diseases. Med Hypotheses. 33:1990;31-41.
2. Hellstrom H. R. Evidence in support of the spasm of resistance vessel concept of ischemic heart disease: an update in 1993. Med Hypotheses. 41:1993;11-22.
3. Sellke F. W., Armstrong M. L., Harrison D. G. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation. 81:1990;1586-1593.
4. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
5. Frishman W. H., Landau A., Cretkovic A. Combination drug therapy with calcium-channel blockers in the treatment of systemic hypertension. J Clin Pharmacol. 33:1993;752-755.
6. Guyton A. C. Abnormal renal function and autoregulation in essential hypertension. Hypertension. 18:1991.
7. Lauritzen M. Pathophysiology of the migraine aura: the spreading depression theory. Brain. 117:1994;199-210.
8. 2-adrenergic vasoconstriction in primary Raynaud's disease. Arthr Rheum. 36:1993;685-690.
9. 123I-IMP-SPECT in migraine between attacks. Headache. 29:1989;344-349.
10. Greenstein D., Gupta N. K., Martin P., Walker D. R., Kester R. C. Impaired thermoregulation in Raynaud's phenomenon. Angiology. 46:1995;603-611.
11. Kahaleh B., Matucci-Cerinic M. Raynaud's phenomenon and scleroderma: dysregulated neuroendothelial control of vascular tone. Arthr Rheum. 38:1995;1-4.
12. Davies P. T., Peatfield R. C., Steiner T. J., Bond R. A., Clifford Rose F. Some clinical comparisons between common and classical migraine: a questionnaire-based study. Cephalalgia. 11:1991;223-227.
13. Fisher J., Mack R. J., Likier H. M., Schiff A. N., Borer J. S. Nifedipine in pulmonary arterial hypertension: importance of Raynaud's phenomenon. Chest. 92:1987;400-405.
14. Kannel W. B., Wilson P. W. F. Comparison of risk profiles for cardiovascular events: implications for prevention. Adv Intern Med. 42:1997;39-66.
15. Stroke. 20:1989;1407-1431.
16. Ellekjær E. F., Wyller T. B., Sverre J. M., Holmen J. Lifestyle factors and risk of cerebral infarction. Stroke. 23:1992;829-834.
17. O'Keeffe S. T., Tsapatsaris N. P., Beetham W. P. Jr. Association between Raynaud's phenomenon and migraine in a random population of hospital employees. J Rheumatol. 20:1993;1187-1188.
18. Miller D., Waters D. D., Warnica W., Szlachcic J., Kreeft J., Théroux P. Is variant angina the coronary manifestation of a generalized vasospastic disorder. N Engl J Med. 304:1981;763-766.
19. Krumholz H. M., Goldberger A. L. Systemic arterial vasospastic syndrome: familial occurrence with variant angina. Am J Med. 92:1992;334-335.
20. Bogousslavsky J., Regli F., Van Melle G., Payot M., Uske A. Migraine stroke. Neurology. 38:1988;223-227.
21. Boortz-Marx R. L., Clark H. B., Taylor S., Wesa K. M., Anderson D. C. Sneddon's syndrome with granulomatous leptomeningeal infiltration. Stroke. 26:1995;492-495.
22. Boone J. L. Stress and hypertension. Prim Care. 18:1991;623-649.
23. Bairey C. N., Krantz D. S., Rozanski A. Mental stress as an acute trigger of ischemic left ventricular dysfunction and blood pressure elevation in coronary artery disease. Am J Cardiol. 66:1990;28G-31G.
24. Rasmussen B. K. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain. 53:1993;65-72.
25. Freedman R. R., Ianni P. Effects of general and thematically relevant stressors in Raynaud's disease. J Psychosom Res. 29:1985;275-280.
26. L'Abbate A., Simonetti I., Carpeggiani C., Michelassi C. Coronary dynamics and mental arithmetic stress in humans. Circulation. 83:1991;II-94-II-192.
27. House A., Dennis M., Mogridge L., Hawton K., Warlow C. Life events and difficulties preceding stroke. J Neurol Neurosurg Psychiatry. 53:1990;1024-1028.
28. Shepherd J. T., Dembroski T. M., Brody M. J. Task Force 3. Biobehavioral mechanisms in coronary artery disease: acute stress. Circulation. 76:1987;I-150-I-157.
29. Sleight P. Smoking and hypertension. Clin Exp Hypertens. 15:1993;1181-1192.
30. Chen T. C., Leviton A., Edelstein S., Ellenberg J. H. Migraine and other diseases in women of reproductive age: the influence of smoking on observed associations. Arch Neurol. 44:1987;1024-1028.
31. Herrick A. L., Rieley F., Schofield D., Hollis S., Braganza J. M., Jayson M. I. V. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol. 21:1994;1477-1483.
32. Panza J. A., Epstein S. E., Quyyumi A. A. Circadian variation in vascular tone and its relation to α-sympathetic vasoconstrictor activity. N Engl J Med. 325:1991;986-990.
33. Fujita M., Franklin D. Diurnal changes in coronary blood flow in conscious dogs. Circulation. 76:1987;488-491.
34. Verdecchia P., Schillaci G., Guerrieri M. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation. 81:1990;528-536.
35. Solomon G. D. Circadian rhythms and migraine. Cleve Clin J Med. 59:1992;326-329.
36. Fox K., Mulcahy D., Keegan J., Wright C. Circadian patterns of myocardial ischemia. Am Heart J. 118:1989;1084-1086.
37. Behar S., Halabi M., Reicher-Reiss H. Circadian variation and possible external triggers of onset of myocardial infarction. Am J Med. 94:1993;395-400.
38. Muller J. E., Ludmer P. L., Willich S. N. Circadian variation in the frequency of sudden cardiac death. Circulation. 75:1987;131-138.
39. Kelly-Hayes M., Wolf P. A., Kase C. S., Brand F. N., McGuirk J. M., D'Agostino R. B. Temporal patterns of stroke onset: the Framingham Study. Stroke. 26:1995;1343-1347.
40. Bønaa K. H., Thelle D. S. Association between blood pressure and serum lipids in a population: the Tromso Study. Circulation. 83:1991;1305-1314.
41. Kozubski W., Stanczyk L. The influence of plasma free fatty acids and cholesterol on the aggregation of blood platelets in migraine patients. Headache. 25:1985;199-203.
42. Holti G. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon. J Int Med Res. 7:1979;473-483.
43. Woo J., Lau E., Lam C. W. K. Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke. 22:1991;203-208.
44. de Forni M., Malet-Martino M. C., Jaillais P. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 10:1992;1795-1801.
45. Stefenelli T., Kuzmits R., Ulrich W., Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 9:1988;552-556.
46. Doll D. C., List A. F., Greco F. A., Hainsworth J. D., Hande K. R., Johnson D. H. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 105:1986;48-51.
47. Bristow M. R., Minobe W. A., Billingham M. E. Anthracycline-associated cardiac and renal damage in rabbits: evidence for mediation by vasoactive substances. Lab Invest. 45:1981;157-168.
48. Loyke H. F. Cold pressor test as a predictor of the severity of hypertension. South Med J. 88:1995;300-304.
49. Drummond P. D., Lance J. W. Neurovascular disturbances in headache patients. Clin Exp Neurol. 20:1984;93-99.
50. Petersen C. L., Hansen A., Frandsen E. Endothelin release and enhanced regional myocardial ischemia induced by cold-air inhalation in patients with stable angina. Am Heart J. 128:1994;511-516.
51. 2synthesis after the cold pressor test in patients with angina at rest. Circulation. 73:1986;409-417.
52. Kuhn F. E., Johnson M. N., Gillis R. A., Visner M. S., Schaer G. L. Effect of cocaine on the coronary circulation and systemic hemodynamics in dogs. J Am Coll Cardiol. 16:1990;1481-1491.
53. Kurth C. D., Monitto C., Albuquerque M. L., Feuer P., Anday E., Shaw L. Cocaine and its metabolites constrict cerebral arterioles in newborn pigs. J Pharmacol Exp Ther. 265:1993;587-591.
54. Knuepfer M. M., Branch C. A., Wehner D. M., Gan Q., Hoang D. Nonadrenergic mechanisms of cocaine-induced regional vascular responses in rats. Can J Physiol Pharmacol. 72:1994;335-343.
55. Dhopesh V., Maany I., Herring C. The relationship of cocaine to headache in polysubstance abusers. Headache. 31:1991;17-19.
56. Daras M., Tuchman A. J., Marks S. Central nervous system infarction related to cocaine abuse. Stroke. 22:1991;1320-1325.
57. Ahlawat S. K., Siwach S. B. Alcohol and coronary artery disease. Int J Cardiol. 44:1994;157-162.
58. Keil J. E., Maricq H. R., Weinrich M. C., McGregor A. R., Diat F. Demographic, social and clinical correlates of Raynaud phenomenon. Int J Epidemiol. 19:1991;221-224.
59. Oda H., Suzuki M., Oniki T., Kishi Y., Numano F. Alcohol and coronary spasm. Angiology. 45:1994;187-197.
60. Gorelick P. B. The status of alcohol as a risk factor for stroke. Stroke. 20:1989;1607-1610.
61. Altura B. M., Altura B. T., Gebrewold A. Alcohol-induced spasms of cerebral blood vessels: relation to cerebrovascular accidents and sudden death. Science. 220:1983;331-333.
62. Altura B. M., Altura B. T., Gebrewold A. Comparative effects of ethanol, acetaldehyde and acetate on arterioles and venules in skeletal muscle: direct in situ studies on the microcirculation and their possible relationship to alcoholic myopathy. Microcirc Endothelium Lymphatics. 6:1990;107-126.
63. Altura B. M., Gebrewold A., Altura B. T., Gupta R. K. Role of brain [Mg2+]i in alcohol-induced hemorrhagic stroke in a rat model: a 31P-NMR in vivo study. Alcohol. 12:1995;131-136.
64. Baron A. D. Hemodynamic actions of insulin. Am J Physiol. 267:1994;E187-E202.
65. Dandona P., James I. M., Newbury P. A., Woollard M. L., Beckett A. G. Cerebral blood flow in diabetes mellitus: evidence of abnormal cerebrovascular reactivity. Br Med J. 2:1978;325-326.
66. Hypertension. 23:1994;145-158.
67. Hamet P. Hypertension and diabetes. Clin Exp Hypertens. 15:1993;1327-1342.
68. Yudkin J. S. Coronary heart disease in diabetes mellitus: three new risk factors and a unifying hypothesis. J Intern Med. 238:1995;21-30.
69. Bronner L. L., Kanter D. S., Manson J. E. Primary prevention of stroke. N Engl J Med. 333:1995;1392-1400.
70. Brands M. W., Hall J. E., Van Vliet B. N., Alonso-Galicia M., Herrera G. A., Zappe D. Obesity and hypertension: roles of hyperinsulinemia, sympathetic nervous system and intrarenal mechanisms. J Nutr. 125:1995;1725S-1731S.
71. Jousilahti P., Tuomilehto J., Vartiainen E., Pekkanen J., Puska P. Body weight, cardiovascular risk factors, and coronary mortality: 15-year follow-up of middle-aged men and women in eastern Finland. Circulation. 93:1996;1372-1379.
72. Stamler J. S., Osborne J. A., Jaraki O. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 91:1993;308-318.
73. Malinow M. R., Levenson J., Giral P. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis. 114:1995;175-183.
74. Boushey C. J., Beresford S. A. A., Omenn G. S., Motulsky A. G. A quantitatiave assessment of plasma homocysteine as a risk factor for vascular disease: probably benefits of increasing folic acid intakes. JAMA. 274:1995;1049-1057.
75. Nygård O., Nordrehaug J. E., Refsum H., Ueland P. M., Farstad M., Vollset S. E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 337:1997;230-236.
76. Man in't Veld A. J. Calcium antagonists in hypertension. Am J Med. 86:1989;6-14.
77. Silberstein S. D., Lipton R. B. Overview of diagnosis and treatment of migraine. Neurology. 44:1994;S6-S16.
78. Coffman J. D. Raynaud's phenomenon: an update. Hypertension. 17:1991;593-602.
79. Cohn P. F. Concomitant use of nitrates, calcium channel blockers, and beta blockers for optimal antianginal therapy. Clin Cardiol. 17:1994;415-421.
80. Kobayashi S., Yamaguchi S., Okada K. Effect of single oral administration of nilvadipine on cerebral blood flow in chronic cerebral infarction. Angiology. 43:1992;801-809.
81. Toole, J. F. Cerebrovascular Disorders, Raven Press, New York, 1990, 151, 160.
82. Gibson R. A. The effect of diets containing fish and fish oils on disease risk factors in humans. Aust N Z J Med. 18:1988;713-722.
83. DiGiacomo R. A., Kremer J. M., Shah D. M. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. Am J Med. 86:1989;158-164.
84. Shrapnel W. S., Calvert G. D., Nestel P. J., Truswell A. S. Diet and coronary heart disease. Med J Aust. 156:1992;S9-S16.
85. Keli S. O., Feskens E. J. M., Kromhout D. Fish consumption and risk of stroke: the Zutphen Study. Stroke. 25:1994;328-332.
86. Jamrozik K., Broadhurst R. J., Anderson C. S., Stewart-Wynne E. G. The role of lifestyle factors in the etiology of stroke: a population-based case-control study in Perth, Western Australia. Stroke. 25:1994;51-59.
87. Orencia A. J., Daviglus M. L., Dyer A. R., Shekelle R. B., Stamler J. Fish consumption and stroke in men: 30-year findings of the Chicago Western Electric Study. Stroke. 27:1996;204-209.
88. 2+and vascular contractility. Miner Electrolyte Metab. 19:1993;323-336.
89. Ma J., Folsom A. R., Melnick S. L. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. J Clin Epidemiol. 48:1995;927-940.
90. Welch K. M. A., Barkley G. L., Tepley N., Ramadan N. M. Central neurogenic mechanisms of migraine. Neurology. 43:1993;S21-S25.
91. Leppert J., Åberg H., Levin K., Ringqvist I. Lower serum magnesium level after exposure to cold in women with primary Raynaud's phenomenon. J Intern Med. 228:1990;235-239.
92. Miwa K., Igawa A., Miyagi Y., Fujita M. Importance of magnesium deficiency in alcohol-induced variant angina. Am J Cardiol. 73:1994;813-816.
93. Altura B. M., Altura B. T. New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. I. Clinical aspects. Magnesium. 4:1985;226-244.
94. Arakawa K. Hypertension and exercise. Clin Exp Hypertens. 15:1993;1171-1179.
95. Lockett D. M. C., Campbell J. F. The effects of aerobic exercise on migraine. Headache. 32:1992;50-54.
96. Lakka T. A., Venäläinen J. M., Rauramaa R., Salonen R., Tuomilehto J., Salonen J. T. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J Med. 330:1994;1549-1554.
97. Ballantyne F. C., Clark R. S., Simpson H. S., Ballantyne D. The effect of moderate physical exercise on the plasma lipoprotein subfractions of male survivors of myocardial infarction. Circulation. 65:1982;913-918.
98. Kavanagh T., Shephard R. J., Tuck J. A., Qureshi S. Depression following myocardial infarction: the effects of distance running. Ann NY Acad Sci. 301:1977;1029-1038.
99. Lehmann M., Keul J., Huber G., Da Prada M. Plasma catecholamines in trained and untrained volunteers during graduated exercise. Int J Sports Med. 2:1981;143-147.
100. Gilligan D. M., Quyyumi A. A., Cannon R. O. III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 89:1994;2545-2551.
101. Collins P. Vascular aspects of ostrogen. Maturitas. 23:1996;217-226.
102. Fettes I. Menstrual migraine: methods of prevention and control. Postgrad Med. 101:1997;67-77.
103. Lekakis J., Mavrikakis M., Emmanuel M. Acute estrogen administration can reverse cold-induced coronary Raynaud's phenomenon in systemic sclerosis. Clin Exp Rheumatol. 14:1996;421-424.
104. Meade T. W., Berra A. Harmone replacement therapy and cardiovascular disease. Br Med Bull. 48:1992;276-308.
105. Förster W., Parratt J. R. The case for low-dose aspirin for the prevention of myocardial infarction: but how low is low. Cardiovasc Drugs Ther. 10:1996;727-734.
106. Hauth J. C., Goldenberg R. L., Parker C. R. Jr. Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol. 168:1993;1083-1091.
107. Buring J. E., Peto R., Hennekens C. H. Low-dose aspirin for migraine prophylaxis. JAMA. 264:1990;1711-1713.
108. Patrono C., Roth G. J. Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen. Stroke. 27:1996;756-760.
109. Guarnieri C., Giordano E., Muscari C., Grossi L., Caldarera C. M. Alpha-tocopheral pretreatment improves endothelium-dependent vasodilation in aortic strips of young and aging rats exposed to oxidative stress. Mol Cell Biochem. 157:1996;223-228.
110. Levine G. N., Frei B., Koulouris S. N., Gerhard M. D., Keaney J. F. Jr, Vita J. A. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 93:1996;1107-1113.
111. Galley H. F., Thornton J., Howdle P. D., Walker B. E., Webster N. R. Combination oral antioxidant supplementation reduces blood pressure. Clin Sci. 92:1997;361-365.
112. Efstratopoulos A. D., Voyaki S. M. Effect of anti-oxidants on acute blood pressure response to smoking in normotensives and hypertenives. J Hypertens. 11:1993;S112-S113.
113. Ghosh S. K., Ekpo E. B., Shah I. U., Girling A. J., Jenkins C., Sinclair A. J. A double-blind, placebo-controlled parallel trial of vitamin C treatment in elderly patients with hypertension. Gerontology. 40:1994;268-272.
114. Schoenen J., Lenaerts M., Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia. 14:1994;328-329.
115. Herrick A. L., Rieley F., Schofield D., Hollis S., Braganza J. M., Jayson M. I. V. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol. 21:1994;1477-1483.
116. McCully, K. S. The Homocysteine Revoluation: Medicine for the New Millennium, Keats Publishing, New Canaan, Connecticut, 1997, 1, 242.
117. Stampfer M. J., Rimm E. B. Epidemiologic evidence for vitamin E in prevention of cardiovascular disease. Am J Clin Nutr. 62:1995;1365S-1369S.
118. Stephens N. G., Parsons A., Schofield P. M. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:1996;781-786.
119. Ness A. R., Powles J. W., Khaw K. T. Vitamin C and cardiovascular disease: a systematic review. J Cardiovasc Risk. 3:1996;513-521.
120. Steiner M., Glantz M., Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr. 62:1995;1381S-1384S.
121. Okrucká A., Pecháň J J., Balažzovjech I. The effect of short-term celiprolol therapy on platelet function in essential hypertension. Cardiology. 82:1993;399-404.
122. 2in migraine: platelet hyperfunction in patients with migraine during headache-free period. Headache. 34:1994;515-518.
123. Lau C. S., McLaren M., Saniabadi A., Belch J. J. F. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. Scand J Rheumatol. 22:1993;97-101.
124. Puri V. K., Verma M., Saxena A. K., Shanker K. Platelet serotonergic mechanisms in ischaemic heart disease. Thromb Res. 57:1990;445-451.
125. Flores N. A., Goulielmos N. V., Seghatchian M. J., Sheridan D. J. Myocardial ischaemia induces platelet activation with adverse electrophysiological and arrhythmogenic effects. Cardiovasc Res. 28:1994;1662-1671.
126. Isaka Y., Kimura K., Uehara A. Platelet aggregability and in vivo platelet deposition in patients with ischemic cerebrovascular disease-evaluation by indium-111-platelet scintigraphy. Thromb Res. 56:1989;739-749.
127. Grignani G., Soffiantino F., Zucchella M. Platelet activation by emotional stress in patients with coronary artery disease. Circulation. 83:1991;III-28-III-36.
128. Colditz G. A., Bonita R., Stampfer M. J. Cigarette smoking and risk of stroke in middle-aged women. N Engl J Med. 318:1988;937-941.
129. Benowitz N. L. Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med. 319:1988;1318-1330.
130. Tofler G. H., Brezinski D., Schafer A. I. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 316:1987;1514-1518.
131. Suehiro A., Kakishita E., Nagai K. The role of platelet hyperfunction in thrombus formation in hyperlipidemia. Thromb Res. 25:1982;331-339.
132. Kuzel T., Exparaz B., Green D., Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer. 65:1990;885-889.
133. Kattlove H. E., Alexander B. The effect of cold on platelets. I. Cold-induced platelet aggregation. Blood. 38:1971;39-48.
134. Kugelmass A. D., Shannon R. P., Yeo E. L., Ware J. A. Intravenous cocaine induces platelet activation in the conscious dog. Circulation. 91:1995;1336-1340.
135. Glassman A. B. Platelet abnormalities in diabetes mellitus. Ann Clin Lab Sci. 23:1993;47-50.
136. Hjermann I. The metabolic cardiovascular syndrome: syndrome X, Reaven's syndrome, insulin resistance syndrome, atherothrombogenic syndrome. J Cardiovasc Pharmacol. 20:1992;S5-S10.
137. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 339:1992;1523-1526.
138. Ortega M. P., Sunkel C., Priego J. G., Statkow P. R. The antithrombogenic in vivo effects of calcium channel blockers in experimental thrombosis in mice. Thromb Haemost. 57:1987;283-285.
139. Atar D., Serebruany V., Poulton J., Godard J., Schneider A., Herzog W. R. Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. J Cardiovasc Pharmacol. 24:1994;603-611.
140. Wang J. S., Jen C. J., Chen H. I. Effects of exercise training and deconditioning on platelet function in men. Arterioscler Thromb Vasc Biol. 15:1995;1668-1674.
141. Keaney J. F. Jr, Vita J. A. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovasc Dis. 38:1995;129-154.
142. Gebara O. C. E., Mittleman M. A., Sutherland P. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 91:1995;1952-1958.
143. Serota H., Kern M. J., Deligonul U., Aguirre F., Caralis D. G. Ergonovine-induced myocardial ischemia without epicardial coronary vasospasm: evidence for ischemia produced by small-vessel vasoconstriction. Am Heart J. 121:1991;1807-1809.
144. el-Tamimi H., Davies G. J., Sritara P., Hackett D., Crea F., Maseri A. Inappropriate constriction of small coronary vessels as a possible cause of a positive exercise test early after successful coronary angioplasty. Circulation. 84:1991;2307-2312.
145. Pupita G., Maseri A., Kaski J. C. Myocardial ischemia caused by distal coronary-artery constriction in stable angina pectoris. N Engl J Med. 323:1990;514-520.
146. Altura B. M., Altura B. T., Gebrewold A. Cocaine induces spasms of cerebral blood vessels: relation to cerebral vascular accidents, strokes and hypertension. Fed Proc. 44:1985;1637.
147. Wigley F. M. Raynaud's phenomenon. Curr Opin Rheumatol. 5:1993;773-784.
148. Doyle A. E. Does hypertension predispose to coronary disease? Conflicting epidemiological and experimental evidence. Laragh J. H., Brenner B. M. Hypertension: Pathophysiology, Diagnosis, and Management. 1990;119-125 Raven Press, New York.
149. Alderman M. H., Madhavan S., Ooi W. L., Cohen H., Sealey J. E., Laragh J. H. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 324:1991;1098-1104.
150. McGill H. C. Jr. The cardiovascular pathology of smoking. Am Heart J. 115:1988;250-257.
151. Moore R. D., Pearson T. A. Moderate alcohol consumption and coronary artery disease: a review. Medicine (Baltimore). 65:1986;242-267.
152. Ross R. Atherosclerosis: a defense mechanism gone awry. Am J Pathol. 143:1993;987-1002.
153. Israel D. H., Gorlin R. Fish oils in the prevention of atherosclerosis. J Am Coll Cardiol. 19:1992;174-185.
154. Mathew R. J., Wilson W. H. Regional cerebral blood flow changes associated with ethanol intoxication. Stroke. 17:1986;1156-1159.
155. Wakabayashi K., Nakamura K., Kono S., Shinchi K., Imanishi K. Alcohol consumption and blood pressure: an extended study of self-defence officials in Japan. Int J Epidemiol. 23:1994;307-311.
156. Hanington E., Jones R. J., Amess J. A. L., Wachowicz B. Migraine: a platelet disorder. Lancet. 2:1981;720-723.
157. Feinberg W. M., Albers G. W., Barnett H. J. M. Guidelines for the management of transient ischemic attacks: from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks of the Stroke Council of the American Heart Association. Circulation. 89:1994;2950-2965.
158. Vicari A. M., Guisti M. C., Luoni R. Platelet function and thrombin activity in patients with recent cerebral transient ischemic attacks. Stroke. 18:1987;892-895.
159. Donnan G. A. Therapy in cerebrovascular disease: current status and future directions. Med J Aust. 155:1991;563-571.
160. A2and prostacyclin. Stroke. 23:1992;1400-1403.
161. Campbell W. B., Halushka P. V. Lipid-derived autacoids: eicosanoids and platelet-activating factor. Hardman J. G., Limbird L. E., Molinoff P. B., Ruddon R. W. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 1996;601-616 McGraw-Hill, New York.
162. Hornig C. R., Bauer T., Simon C., Trittmacher S., Dorndorf W. Hemorrhagic transformation in cardioembolic cerebral infarction. Stroke. 24:1993;465-468.
163. Cole A. J., Aubé M. Migraine with vasospasm and delayed intracerebral hemorrhage. Arch Neurol. 47:1990;53-56.
164. Shuaib A., Metz L., Hing T. Migraine and intracerebral hemorrhage. Cephalalgia. 9:1989;59-61.
165. Meza I., Estrada C. A., Montalvo J. A., Hidalgo W. N., Andresen J. Cerebral infarction associated with cocaine use. Henry Ford Hosp Med J. 37:1989;50-51.
166. Wojak J. C., Flamm E. S. Intracranial hemorrhage and cocaine use. Stroke. 18:1987;712-715.